secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2024-01-02T23:59:59+00:00
Accession:  0001193125-24-000240
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos appoints new director, cash runway into Q3 2024, plans reverse stock split
--------------------------------------------------------------------------------

- Dale Curtis Hogue, Jr. appointed independent director effective Dec 29, 2023; receives initial 150k option grant vesting over 36 months.
- Cash resources expected to fund operations into Q3 2024 due to cost-saving measures.
- Company taking steps to implement reverse stock split approved by stockholders in June 2023.
- No assurance reverse split will increase stock price or cure Nasdaq listing deficiencies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312524000240/0001193125-24-000240-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312524000240/d682377d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-000240

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer